Comment on: Redefining extended-spectrum β-lactamases: Balancing science and clinical need

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 1, 2009, Pages 212-213

  Bush, Karen ^a   Jacoby, George A ^b   Amicosante, Gianfranco ^c   Bonomo, Robert A ^d   Bradford, Patricia ^e   Cornaglia, Giuseppe ^f   Garau, Javier ^g   Giamarellou, Helen ^h   Jarlier, Vincent ⁱ   Martinez Martinez, Luis ^j   Miriagou, Vivi ^k   Palzkill, Timothy ^l   Pascual, Alvaro ^m   Rodriguez Baño, Jesus ⁿ   Rossolini, Gian Maria ^o   Sougakoff, Wladimir ^p   Vatopoulos, Alkiviadis ^q  

^a INDIANA UNIVERSITY   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^e WYETH RESEARCH   (United States)

^f UNIVERSITY OF VERONA   (Italy)

^g HOSPITAL MÚTUA DE TERRASSA   (Spain)

^h UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^j HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^k HELLENIC PASTEUR INSTITUTE   (Greece)

^l BAYLOR COLLEGE OF MEDICINE   (United States)

^m UNIVERSITY OF SEVILLE   (Spain)

ⁿ HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^o UNIVERSITY OF SIENA   (Italy)

^p SORBONNE UNIVERSITÉ   (France)

^q NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

more..

Author keywords

Carbapenemases; Cephalosporinases; ESBLs; Nomenclature

Indexed keywords

BETA LACTAM; BETA LACTAMASE AMPC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; MONOBACTAM DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTERIAL CHROMOSOME; ENZYME SYNTHESIS; HYDROLYSIS; NOTE; PLASMID; PROTEIN EXPRESSION;

ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAMASES; BETA-LACTAMS; DRUG RESISTANCE, BACTERIAL; HUMANS; TERMINOLOGY AS TOPIC;

EID: 67249148433     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp104     Document Type: Note

References (6)

1. Ambler RP. The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 1980; 289: 321-31.
2. Richmond MH, Sykes RB. The β-lactamases of Gram-negative bacteria and their possible physiological role. In: Rose AH, Tempest DW, eds. Advances in Microbial Physiology. New York: Academic Press, 1973; 31-88.
3. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-33.
4. Philippon A, Labia R, Jacoby G. Extended-spectrum β-lactamases. Antimicrob Agents Chemother 1989; 33: 1131-6.
5. Giske CG, Sundsfjord AS, Kahlmeter G et al. Redefining extended-spectrum β-lactamases: Balancing science and clinical need. J Antimicrob Chemother 2009; 63: 1-4.
6. Paterson DL, Ko WC, Von Gottberg A et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: Implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12.